SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
PureTech Health plc (PRTC) trades at a trailing P/E of 7.5, forward P/E of 4.4. Trailing earnings yield is 13.36%, forward earnings yield 22.83%. PEG 0.04 (Peter Lynch undervalued ≤1.0). Graham Number is $27.63.
Criteria proven by this page:
- VALUE (91/100, Pass) — P/E is below market average (7.5); PEG ≤ 1.0 — Peter Lynch undervalued (0.04); analyst target implies upside (+219%); earnings yield beats bond yields (13.36%).
- Forward P/E 4.4 (down from trailing 7.5) — analysts expect earnings to grow, which would improve the valuation.
- PEG Ratio 0.04 — below 1.0 suggests the stock is undervalued relative to its earnings growth rate (Peter Lynch criterion).
- Trailing Earnings Yield 13.36% — exceeds typical bond yields (~4.3%), making equity attractive vs fixed income. Forward yield improves to 22.83% as earnings recover.
- Analyst consensus target $57.00 (+219% upside) — significant upside potential according to Wall Street analysts.
Overall SharesGrow Score: 72/100 with 4/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
91/100
Price-to-Earnings & upside
Proven by this page
~
HEALTH
67/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — PRTC
Valuation Multiples
P/E (TTM)7.5
Forward P/E4.4
PEG Ratio0.04
Forward PEG0.04
P/B Ratio1.01
P/S Ratio66.92
EV/EBITDA2.8
Per Share Data
EPS (TTM)$2.16
Forward EPS (Est.)$4.08
Book Value / Share$15.72
Revenue / Share$0.25
FCF / Share$-4.27
Yields & Fair Value
Earnings Yield13.36%
Forward Earnings Yield22.83%
Dividend Yield0.00%
Graham Number$27.63
Analyst Target$57.00 (+219%)
Historical Valuation
| Year |
P/E (TTM) |
PEG Ratio |
P/B Ratio |
P/S Ratio |
Dividend Yield |
| 2015 |
-18.1 |
0.31 |
3.15 |
60.76 |
- |
| 2016 |
-18.1 |
0.00 |
4.97 |
199.42 |
- |
| 2017 |
30.0 |
-0.20 |
4.32 |
1,425.42 |
0.01% |
| 2018 |
-24.1 |
0.10 |
3.81 |
64.16 |
0.00% |
| 2019 |
2.7 |
0.00 |
1.69 |
129.60 |
0.01% |
| 2020 |
270.0 |
-2.74 |
2.41 |
193.75 |
- |
| 2021 |
-17.5 |
0.02 |
1.79 |
106.26 |
- |
| 2022 |
-17.7 |
1.24 |
1.65 |
426.98 |
- |
| 2023 |
-11.9 |
-0.36 |
1.68 |
233.82 |
- |
| 2024 |
9.3 |
-0.05 |
1.20 |
103.10 |
- |
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2015 |
$-2.10 |
$11.74M |
$-39.39M |
-335.5% |
| 2016 |
$-2.10 |
$4.43M |
$-48.79M |
-1101.2% |
| 2017 |
$1.10 |
$650K |
$30.87M |
4749.1% |
| 2018 |
$-1.60 |
$16.37M |
$-43.65M |
-266.7% |
| 2019 |
$14.40 |
$8.69M |
$421.14M |
4847.4% |
| 2020 |
$0.20 |
$8.34M |
$4.57M |
54.8% |
| 2021 |
$-2.10 |
$9.98M |
$-62.71M |
-628.4% |
| 2022 |
$-1.80 |
$2.09M |
$-37.06M |
-1773.4% |
| 2023 |
$-2.40 |
$3.33M |
$-65.7M |
-1972.9% |
| 2024 |
$2.00 |
$4.32M |
$53.51M |
1240.1% |
Analyst Estimates
| Year |
EPS (Avg) |
EPS Range |
Revenue (Avg) |
Revenue Range |
Analysts |
| 2026 |
$-6.47 |
$-6.47 – $-6.47 |
$49.5M |
$49.5M – $49.5M |
1 |
| 2027 |
$-6.93 |
$-6.93 – $-6.93 |
$228.2M |
$228.2M – $228.2M |
1 |
| 2028 |
$4.08 |
$4.08 – $4.08 |
$473.8M |
$473.8M – $473.8M |
1 |
